TY - JOUR
T1 - Fructan-sensitive children with irritable bowel syndrome have distinct gut microbiome signatures
AU - Chumpitazi, Bruno P.
AU - Hoffman, Kristi L.
AU - Smith, Daniel P.
AU - McMeans, Ann R.
AU - Musaad, Salma
AU - Versalovic, James
AU - Petrosino, Joseph F.
AU - Shulman, Robert J.
N1 - Funding Information:
Financial and/or intellectual support was provided by National Instittutes of Health (NIH) K23 DK101688 (BPC), R03 DK117219 (BPC and JFP), UH3 DK083990 (JV), the United States Department of Agriculture/Agriculture Research Service under Cooperative Agreement number 6250‐51000‐043 (RJS) and P30 DK056338 which funds the Texas Medical Center Digestive Disease Center.
Funding Information:
Financial and/or intellectual support was provided by National Instittutes of Health (NIH) K23 DK101688 (BPC), R03 DK117219 (BPC and JFP), UH3 DK083990 (JV), the United States Department of Agriculture/Agriculture Research Service under Cooperative Agreement number 6250-51000-043 (RJS) and P30 DK056338 which funds the Texas Medical Center Digestive Disease Center. We thank the subjects who participated and Adetola Vaughan, Vanessa Thyne, Denisse Castaneda and Deshara Emerson for their help with research coordination. Declaration of personal interests: BPC previously provided consultancy to Mead-Johnson Nutrition; JV received unrestricted research support from Biogaia AB (Stockholm, Sweden) and serves on the Scientific Advisory Boards of Biomica, Plexus Worldwide and Seed Health; JFP is the founder and chief scientific officer of Diversigen, Inc; RJS previously provided consultancy for Nutrinia, IMHealth and Biogaia AB, and previously received restricted research support from Mead-Johnson.
Publisher Copyright:
© 2020 John Wiley & Sons Ltd
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/2
Y1 - 2021/2
N2 - Background: Dietary fructans may worsen gastrointestinal symptoms in children with irritable bowel syndrome (IBS). Aim: To determine whether gut microbiome composition and function are associated with childhood IBS fructan-induced symptoms. Methods: Faecal samples were collected from 38 children aged 7-17 years with paediatric Rome III IBS, who previously completied a double-blind, randomised, placebo-controlled crossover (fructan vs maltodextrin) trial. Fructan sensitivity was defined as an increase of ≥30% in abdominal pain frequency during the fructan diet. Gut microbial composition was determined via 16Sv4 rDNA sequencing. LEfSe evaluated taxonomic composition differences. Tax4Fun2 predicted microbial fructan metabolic pathways. Results: At baseline, 17 fructan-sensitive (vs 21 fructan-tolerant) subjects had lower alpha diversity (q < 0.05) and were enriched in the genus Holdermania. In contrast, fructan-tolerant subjects were enriched in 14 genera from the class Clostridia. During the fructan diet, fructan-sensitive (vs tolerant) subjects were enriched in both Agathobacter (P = 0.02) and Cyanobacteria (P = 0.0001). In contrast, fructan-tolerant subjects were enriched in three genera from the Clostridia class. Comparing the fructan vs maltodextrin diet, fructan-sensitive subjects had a significantly increased relative abundance of Bifidobacterium (P = 0.02) while fructan-tolerant subjects had increased Anaerostipes (P = 0.03) during the fructan diet. Only fructan-sensitive subjects had a trend towards increased predicted β-fructofuranosidase during the fructan vs maltodextrin diet. Conclusions: Fructan-sensitive children with IBS have distinct gut microbiome signatures. These microbiome signatures differ both at baseline and in response to a fructan challenge.
AB - Background: Dietary fructans may worsen gastrointestinal symptoms in children with irritable bowel syndrome (IBS). Aim: To determine whether gut microbiome composition and function are associated with childhood IBS fructan-induced symptoms. Methods: Faecal samples were collected from 38 children aged 7-17 years with paediatric Rome III IBS, who previously completied a double-blind, randomised, placebo-controlled crossover (fructan vs maltodextrin) trial. Fructan sensitivity was defined as an increase of ≥30% in abdominal pain frequency during the fructan diet. Gut microbial composition was determined via 16Sv4 rDNA sequencing. LEfSe evaluated taxonomic composition differences. Tax4Fun2 predicted microbial fructan metabolic pathways. Results: At baseline, 17 fructan-sensitive (vs 21 fructan-tolerant) subjects had lower alpha diversity (q < 0.05) and were enriched in the genus Holdermania. In contrast, fructan-tolerant subjects were enriched in 14 genera from the class Clostridia. During the fructan diet, fructan-sensitive (vs tolerant) subjects were enriched in both Agathobacter (P = 0.02) and Cyanobacteria (P = 0.0001). In contrast, fructan-tolerant subjects were enriched in three genera from the Clostridia class. Comparing the fructan vs maltodextrin diet, fructan-sensitive subjects had a significantly increased relative abundance of Bifidobacterium (P = 0.02) while fructan-tolerant subjects had increased Anaerostipes (P = 0.03) during the fructan diet. Only fructan-sensitive subjects had a trend towards increased predicted β-fructofuranosidase during the fructan vs maltodextrin diet. Conclusions: Fructan-sensitive children with IBS have distinct gut microbiome signatures. These microbiome signatures differ both at baseline and in response to a fructan challenge.
UR - http://www.scopus.com/inward/record.url?scp=85097511406&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097511406&partnerID=8YFLogxK
U2 - 10.1111/apt.16204
DO - 10.1111/apt.16204
M3 - Article
C2 - 33314183
AN - SCOPUS:85097511406
VL - 53
SP - 499
EP - 509
JO - Alimentary Pharmacology and Therapeutics
JF - Alimentary Pharmacology and Therapeutics
SN - 0269-2813
IS - 4
ER -